Search research articles
Contact Us
Filters
Showing results (311-320 of 321) with videos related to
Page
of 33
Sort By:
Military Medicine
|
November 26, 2020
Demographic and Functional Characteristics of National Veterans Wheelchair Games Participants: A Cross-sectional Study
Cecelia Rose Lee-Hauser, Richard M Schein, Vince J Schiappa, et al.
The New England Journal of Medicine
|
June 27, 1996
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group
C J Fisher, J M Agosti, S M Opal, et al.
JAMA
|
August 28, 1991
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group
R L Greenman, R M Schein, M A Martin, et al.
Critical Care Medicine
|
March 1, 1993
Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group
C J Fisher, S M Opal, J F Dhainaut, et al.
Assistive Technology : the Official Journal of RESNA
|
June 18, 2019
Functional mobility assessment is reliable and correlated with satisfaction, independence and skills
Debora Caires Paulisso, Mark R Schmeler, Richard M Schein, et al.
Critical Care Medicine
|
March 11, 2003
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure
Edward Abraham, Chris Naum, Venkata Bandi, et al.
Critical Care Medicine
|
June 1, 1995
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group
R C Bone, R A Balk, A M Fein, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
May 8, 2001
Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part one: rationale and hypothesis
W Lorenz, B Stinner, A Bauhofer, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
June 8, 2001
Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol for a controlled clinical trial developed by consensus of an international study group. Part two: design of the study
A Bauhofer, W Lorenz, B Stinner, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
June 21, 2001
Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part three: individual patient, complication algorithm and quality manage
B Stinner, A Bauhofer, W Lorenz, et al.
Page
of 33
Search research articles
Search
Showing results (311-320 of 321) with videos related to
Sort By:
Page
of 33
Military Medicine
|
November 26, 2020
Demographic and Functional Characteristics of National Veterans Wheelchair Games Participants: A Cross-sectional Study
Cecelia Rose Lee-Hauser, Richard M Schein, Vince J Schiappa, et al.
The New England Journal of Medicine
|
June 27, 1996
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group
C J Fisher, J M Agosti, S M Opal, et al.
JAMA
|
August 28, 1991
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group
R L Greenman, R M Schein, M A Martin, et al.
Critical Care Medicine
|
March 1, 1993
Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group
C J Fisher, S M Opal, J F Dhainaut, et al.
Assistive Technology : the Official Journal of RESNA
|
June 18, 2019
Functional mobility assessment is reliable and correlated with satisfaction, independence and skills
Debora Caires Paulisso, Mark R Schmeler, Richard M Schein, et al.
Critical Care Medicine
|
March 11, 2003
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure
Edward Abraham, Chris Naum, Venkata Bandi, et al.
Critical Care Medicine
|
June 1, 1995
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group
R C Bone, R A Balk, A M Fein, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
May 8, 2001
Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part one: rationale and hypothesis
W Lorenz, B Stinner, A Bauhofer, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
June 8, 2001
Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol for a controlled clinical trial developed by consensus of an international study group. Part two: design of the study
A Bauhofer, W Lorenz, B Stinner, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
June 21, 2001
Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part three: individual patient, complication algorithm and quality manage
B Stinner, A Bauhofer, W Lorenz, et al.
Page
of 33